Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups such as the elderly, those with underlying respiratory or cardiac disease, and those with compromised immune systems (e.g., bone marrow transplant patients).

About Motavizumab

Motavizumab, formerly known as Numax(R), is an investigational humanized MAb being evaluated for its potential to prevent serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease. Phase 1 and Phase 2 study data have been reported showing that motavizumab appears to have a similar safety and pharmacokinetic profile to Synagis in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract. In its first pivotal trial, which was a head-to-head comparative trial with Synagis, motavizumab demonstrated a 26-percent reduction in RSV hospitalizations due to RSV and a 50-percent reduction in the incidence of RSV lower respiratory tract infections requiring outpatient management, its secondary endpoint.

About Synagis

Synagis is the only monoclonal antibody approved by the FDA to help prevent an infectious disease. Synagis was approved for use in the United States in 1998, Europe in 1999, and Japan in 2002. Synagis is currently available in 62 countries.

Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RS
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... has revolutionized healthcare and is essential in the detection ... protocols ensure that patients, physicians, and technicians are exposed ... providing accurate results and diagnostic information. ... be balanced with the benefits of that procedure. Alarmist ...
... Muscular Dystrophy Association ( MDA ) has awarded $750,000 to ... development of an experimental drug that may become a viable ... The funding comes from MDA Venture Philanthropy (MVP), ... is one of nine types of muscular dystrophy, a group ...
Cached Medicine Technology:AAPM Cautions that Patients Should Not Forgo Essential Medical Imaging 2MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 2MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 3MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 4
(Date:4/23/2014)... high-energy particles, simulating conditions astronauts would face on a ... slower reaction times, even when the radiation exposure is ... which affected a large subset, but far from ... to protein changes in the brain, the scientists say. ... suggest it may be possible to develop a biological ...
(Date:4/23/2014)... tract has long been considered to be between 180 ... have used refined microscopic techniques that indicate a much ... gastro-intestinal tract is only as large as a normal ... tract, which passes from the mouth through the esophagus ... about 5 meters in a normal adult, and is ...
(Date:4/23/2014)... American Gastroenterological Association (AGA) Research Foundation is pleased ... AGA Research Scholar Awards program, launched in 1984, ... research careers in digestive diseases. This year, the ... allowing for three consecutive years of funding. , ... are paving the way for promising research developments ...
(Date:4/23/2014)... 21, 2014 Five for-profit and non-profit organizations ... million in Proof of Concept grants to accelerate ... commercial products, the Life Sciences Discovery Fund (LSDF) ... Mentoring Program grant to the Washington Biotechnology & ... network to train the next generation of entrepreneurs ...
(Date:4/23/2014)... journal Oncotarget , explored tumour heterogeneity ... own DNA signatures within the same cancer. Such ... targeted treatment strategies. , Firstly they confirmed the ... the KRAS or BRAF mutation. Secondly, they found ... mutation have that specific mutation present uniformly throughout ...
Breaking Medicine News(10 mins):Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
... fruit fly,s immune system can tell time, researchers at ... how hard it punches back against infections depends on ... could have implications for human health, too. , Working ... cycle and with syringes small enough to inject measured ...
... LLC will be featured in an upcoming episode. , ... Deerfield Beach, ... are pleased to announce that Gradient Medical, LLC will be featured in ... Tomorrow,s Health Solutions Today., , ,Pain is a national public healthcare crisis. ...
... of a breast cancer prevention study using exemestane (Aromasin) ... ongoing phase II study details reported today, by Jennifer ... Comprehensive Cancer Center at the San Antonio Breast Cancer ... who are at an increased risk of developing breast ...
... Expression of the microtubule-binding protein Tau is not a ... paclitaxel chemotherapy, according to research led by The University ... today, Dec. 13, at the CRTC-AACR San Antonio Breast ... predict survival, yet in an unexpected way. ...
... areas that show up light on a mammogram - ... "why" remains to be answered. Now, by examining dense ... volunteers, researchers from Mayo Clinic have found several potential ... poster form at the Cancer Therapy & Research Center-American ...
... the finish line in second place at the 2008 Ford Ironman ... for 34 year-old Jason Fowler, who was one of five wheelchair ... the Pacific Ocean, using only his arms, a 112-mile bike ride ... that Jason completed in a racing wheelchair in 90 degree heat. ...
Cached Medicine News:Health News:Snoring or soaring? Strength of fruit-fly immune system varies 2Health News:Snoring or soaring? Strength of fruit-fly immune system varies 3Health News:"The Economic Report" Show to Feature Gradient Medical, LLC 2Health News:Tau protein expression predicts breast cancer survival -- though not as expected 2Health News:Tau protein expression predicts breast cancer survival -- though not as expected 3Health News:Mayo researchers find potential links between breast density and breast cancer risk 2Health News:Mayo researchers find potential links between breast density and breast cancer risk 3Health News:Video: Paralyzed From the Chest Down, Triathlete Takes Second in the Handcycle Division of the Ford Ironman World Championship 2Health News:Video: Paralyzed From the Chest Down, Triathlete Takes Second in the Handcycle Division of the Ford Ironman World Championship 3Health News:Video: Paralyzed From the Chest Down, Triathlete Takes Second in the Handcycle Division of the Ford Ironman World Championship 4Health News:Video: Paralyzed From the Chest Down, Triathlete Takes Second in the Handcycle Division of the Ford Ironman World Championship 5
Solid lower plate with outside width 28 mm. Open upper plate. Serrated handle with locking thumb screw and polished finish. Right....
Round solid lower plate. Open upper plate with inside diameter 15 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
This cross action forcep has delicate tips for grasping the capsule. The forcep has an iris stop to prevent inadvertent grasping of the iris....
Medicine Products: